- Home
- GLOB vs MDGL Comparison
GLOB vs MDGL Comparison
Compare GLOB & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLOB
- MDGL
- Stock Information
- Founded
- GLOB 2003
- MDGL 2011
- Country
- GLOB Luxembourg
- MDGL United States
- Employees
- GLOB N/A
- MDGL N/A
- Industry
- GLOB EDP Services
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- GLOB Technology
- MDGL Health Care
- Exchange
- GLOB Nasdaq
- MDGL Nasdaq
- Market Cap
- GLOB 9.2B
- MDGL 7.4B
- IPO Year
- GLOB 2014
- MDGL N/A
- Fundamental
- Price
- GLOB $229.30
- MDGL $347.45
- Analyst Decision
- GLOB Buy
- MDGL Buy
- Analyst Count
- GLOB 19
- MDGL 14
- Target Price
- GLOB $230.95
- MDGL $347.33
- AVG Volume (30 Days)
- GLOB 523.3K
- MDGL 669.2K
- Earning Date
- GLOB 11-14-2024
- MDGL 10-31-2024
- Dividend Yield
- GLOB N/A
- MDGL N/A
- EPS Growth
- GLOB 7.25
- MDGL N/A
- EPS
- GLOB 3.84
- MDGL N/A
- Revenue
- GLOB $2,353,911,000.00
- MDGL $76,813,000.00
- Revenue This Year
- GLOB $17.61
- MDGL N/A
- Revenue Next Year
- GLOB $15.25
- MDGL $193.46
- P/E Ratio
- GLOB $59.71
- MDGL N/A
- Revenue Growth
- GLOB 17.35
- MDGL N/A
- 52 Week Low
- GLOB $151.68
- MDGL $168.25
- 52 Week High
- GLOB $251.50
- MDGL $368.29
- Technical
- Relative Strength Index (RSI)
- GLOB 58.38
- MDGL 69.35
- Support Level
- GLOB $199.84
- MDGL $272.72
- Resistance Level
- GLOB $238.32
- MDGL $342.58
- Average True Range (ATR)
- GLOB 7.68
- MDGL 20.02
- MACD
- GLOB -0.72
- MDGL -0.66
- Stochastic Oscillator
- GLOB 76.56
- MDGL 78.19
About GLOB Globant S.A.
Globant SA is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2003 in Argentina but is currently headquartered in Luxembourg and primarily serves clients in the U.S. and Latin America. Globant's client base is relatively concentrated in the media and entertainment and financial services industries.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.